Klin Farmakol Farm. 2005;19(4):229-234

Osteoporosis: goals of treatment

Jan Štěpán
3. interní klinika, 1. LF UK Praha, Osteocentrum VFN, Praha

Ageing may be accompanied by osteoporosis which is not an unavoidable consequence of ageing. There are no characteristic clinical symptoms of osteoporosis. However, osteoporosis may result in low-trauma fractures. Vertebral and hip fractures result in untimely death, disability and dependence of afflicted patients. Osteoporosis can be early diagnosed, prevented and treated before fractures occur. It should not be treated before conclusively diagnosed. The pharmacological treatment of osteoporosis should be stratified with respect to the main factors of the 10-year absolute risk of fracture, i.e. bone loss, age and prevalent fracture.

Keywords: Key words: osteoporosis, risk of fracture, antiresorption therapy, anabolic therapy.

Published: January 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Štěpán J. Osteoporosis: goals of treatment. Klin Farmakol Farm. 2005;19(4):229-234.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. NIH Consensus Development Panel. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001; 285 (6): 785-795. Go to original source... Go to PubMed...
    2. Schuit SCE, van der Klift M, Weel AEAM, de Laet CEDH, Burger H, Seeman E, et al. Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study. Bone 2004; 34 (1): 195-202. Go to original source... Go to PubMed...
    3. Hui SL, Slemenda CW, Johnston CC, Jr. Age and bone mass as predictors of fracture in a prospective study. J Clin Invest 1988; 81 (6): 1804-1809. Go to original source... Go to PubMed...
    4. Schaffler MB, Choi K, Milgrom C. Aging and matrix microdamage accumulation in human compact bone. Bone 1995; 17 (6): 521-525. Go to original source... Go to PubMed...
    5. Štěpán JJ, Havelka S, Kamberská Z, Bernátová M. Epidemiologie der Osteoporose in der Tschechischen Republik. J Mineralstoffwechsel 2002; 9 (3): 7-13.
    6. Lindsay R, Silverman SL, Cooper C, Hanley DA, Barton I, Broy SB, et al. Risk of new vertebral fracture in the year following a fracture. JAMA 2001; 285 (3): 320-323. Go to original source... Go to PubMed...
    7. Štěpán JJ, Alenfeld F, Boivin G, Feyen JH, Lakatos P. Mechanisms of action of antiresorptive therapies of postmenopausal osteoporosis. Endocr Regul 2003; 37 (4): 225-238. Go to PubMed...
    8. Lips P. Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications. Endocr Rev 2001; 22 (4): 477-501. Go to original source... Go to PubMed...
    9. Borah B, Dufresne TE, Chmielewski PA, Johnson TD, Chines A, Menhart MD. Risedronate preserves bone architecture in postmenopausal women with osteoporosis as measured by three-dimensional microcomputed tomography. Bone 2004; 34 (4): 736-746. Go to original source... Go to PubMed...
    10. Zajíčková K, Žofková I. Osteoporosis: genetic analysis of multifactorial disease. Endocr Regul 2003; 37 (1): 31-44. Go to PubMed...
    11. Burckhardt P, Havelka S, Lips P, Meunier PJ, Peterlik M, Scharla S, et al. Konsensuskonferenz uber die optimale Kalzium- und Vitamin D-Zufuhr. J Miner Stoffwechs 1995; 2 (4): 5-11.
    12. Bayer M, S. K, Feber J, Gut J. Metabolická onemocnění skeletu u dětí. Praha: Grada Publishing; 2002.
    13. Chapuy MC, Pamphile R, Paris E, Kempf C, Schlichting M, Arnaud S, et al. Combined calcium and vitamin D3 supplementation in elderly women: confirmation of reversal of secondary hyperparathyroidism and hip fracture risk: the Decalyos II study. Osteoporos Int 2002; 13 (3): 257-264. Go to original source... Go to PubMed...
    14. Writing Group for the Women's Health Initiative I. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002; 288 (3): 321-333. Go to original source... Go to PubMed...
    15. Tremollieres FA, Pouilles JM, Ribot C. Withdrawal of hormone replacement therapy is associated with significant vertebral bone loss in postmenopausal women. Osteoporos Int 2001; 12 (5): 385-390. Go to original source... Go to PubMed...
    16. Kanis JA, Johnell O, Oden A, De Laet C, Jonsson B, Dawson A. Ten-year risk of osteoporotic fracture and the effect of risk factors on screening strategies. Bone 2002; 30 (1): 251-258. Go to original source... Go to PubMed...
    17. Naves M, Diaz Lopez JB, Gomez C, Rodriguez Rebollar A, Rodriguez Garcia M, Cannata Andia JB. The effect of vertebral fracture as a risk factor for osteoporotic fracture and mortality in a Spanish population. Osteoporos Int 2003; 14 (6): 520-524. Go to original source... Go to PubMed...
    18. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999; 282 (7): 637-645. Go to original source... Go to PubMed...
    19. Cauley JA, Norton L, Lippman ME, Eckert S, Krueger KA, Purdie DW, et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat 2001; 65 (2): 125-134. Go to original source... Go to PubMed...
    20. Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett Connor E, Musliner TA, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998; 280 (24): 2077-2082. Go to original source... Go to PubMed...
    21. Heaney RP, Zizic TM, Fogelman I, Olszynski WP, Geusens P, Kasibhatla C, et al. Risedronate reduces the risk of first vertebral fracture in osteoporotic women. Osteoporos Int 2002; 13 (6): 501-505. Go to original source... Go to PubMed...
    22. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999; 282 (14): 1344-1352. Go to original source... Go to PubMed...
    23. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996; 348 (9041): 1535-1541. Go to original source... Go to PubMed...
    24. Chesnut III CH, Skag A, Christiansen C, Recker R, Stakkestad JA, Hoiseth A, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004; 19 (8): 1241-1249. Go to original source... Go to PubMed...
    25. Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Spector TD, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004; 350 (5): 459-468. Go to original source... Go to PubMed...
    26. Chesnut CH, Silverman S, Andriano K, Genant H, Gimona A, Harris S, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med 2000; 109 (4): 267-276. Go to original source... Go to PubMed...
    27. McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001; 344 (5): 333-340. Go to original source... Go to PubMed...
    28. Meunier PJ, Sebert JL, Reginster JY, Briancon D, Appelboom T, Netter P, et al. Fluoride salts are no better at preventing new vertebral fractures than calcium-vitamin D in postmenopausal osteoporosis: the FAVOStudy. Osteoporos Int 1998; 8 (1): 4-12. Go to original source... Go to PubMed...
    29. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, et al. Effect of parathyroid hormone (134) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001; 344 (19): 1434-1441. Go to original source... Go to PubMed...
    30. Felsenberg D, Silman AJ, Lunt M, Armbrecht G, Ismail AA, et al. Incidence of vertebral fracture in Europe: results from the European Prospective Osteoporosis Study (EPOS). J Bone Miner Res 2002; 17 (4): 716-724. Go to original source... Go to PubMed...

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.